Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
Delayed Hong Kong Stock Exchange  -  03:08:49 2023-02-03 am EST
65.95 HKD   -3.16%
02/02Wuxi Biologics Cayman : XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara's Oncology DFC Program
PU
01/19First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
AQ
01/17Trending: Wuxi Biologics Shareholder Plans Block Sale
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WuXi Biologics Releases New cGMP Drug Product Manufacturing Facility to Support End-To-End Services for Diversified Modalities

10/23/2022 | 08:30pm EST

WuXi Biologics announced its new drug product (DP) facility – named DP8 – located in Hangzhou, China, has completed the first batch of GMP manufacturing. The DP8 facility is the tenth operational drug product facility in WuXi Biologics' global network. The single-use-system-based DP8 facility features SA25 robotic, sterile filling technology with two completely segregated filling lines, as well as an aseptic formulation isolator dedicated to the preparation of alum-adjuvanted vaccines.

It also has mRNA-LNP encapsulation technologies, with a processing capacity of 10 L per hour. The DP8 facility provides flexible dosage forms, including vials (2R to 20R) and prefilled syringes (1 mL to 3 mL, long and normal). Combining the DP8 facility with the company's operational development labs and drug substance facility (MFG14) located in the same area, WuXi Biologics can provide end-to-end solutions from DNA to drug substance manufacturing and drug product fill & finish for various modalities – such as enzymes, antibody fragments, recombinant proteins, virus-like particle (VLP), plasmid DNA and mRNA – within a centralized region.


ę S&P Capital IQ 2022
All news about WUXI BIOLOGICS (CAYMAN) INC.
02/02Wuxi Biologics Cayman : XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara..
PU
01/19First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment..
AQ
01/17Trending: Wuxi Biologics Shareholder Plans Block Sale
DJ
01/17WuXi Biologics (Cayman) Substantial Shareholder to Place 56 Million Shares; Shares Slip..
MT
01/17Wuxi Biologics' Major Shareholder Plans to Sell 1.3% Stake
CI
01/17Wuxi Biologics Drops After Major Shareholder Plans to Sell 1.3% Stake
DJ
01/12Wuxi Biologics Cayman : 41th Annual J.P. Morgan Healthcare Conference Presentation (in
PU
01/05WuXi Biologics signs exclusive deal with GSK
AN
01/05Trending: Wuxi Biologics Licenses Tumor Antibodies to GSK
DJ
01/04Wuxi Biologics And Gsk Enter Into License Agreement On Multiple Novel Bi- & Multi-Speci..
RE
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2022 15 253 M 2 256 M 2 256 M
Net income 2022 4 790 M 708 M 708 M
Net cash 2022 5 060 M 748 M 748 M
P/E ratio 2022 50,9x
Yield 2022 -
Capitalization 240 B 35 517 M 35 517 M
EV / Sales 2022 15,4x
EV / Sales 2023 11,2x
Nbr of Employees 10 593
Free-Float 84,3%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 29
Last Close Price 56,84 CNY
Average target price 90,18 CNY
Spread / Average Target 58,6%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors